SCYNEXIS (NASDAQ:SCYX) issued its quarterly earnings data on Tuesday. The company reported $0.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.18, MarketWatch Earnings reports. SCYNEXIS had a negative return on equity of 105.78% and a negative net margin of 12,011.72%. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.06 million.
Shares of SCYX traded up $0.03 during mid-day trading on Wednesday, reaching $0.87. 147,700 shares of the company’s stock traded hands, compared to its average volume of 452,262. The stock has a market cap of $41.61 million, a price-to-earnings ratio of -0.86 and a beta of 0.59. SCYNEXIS has a 12 month low of $0.82 and a 12 month high of $2.45. The company has a debt-to-equity ratio of 0.35, a quick ratio of 4.30 and a current ratio of 4.30.
SCYX has been the topic of several analyst reports. Maxim Group reduced their price objective on SCYNEXIS from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 16th. Zacks Investment Research raised SCYNEXIS from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research note on Thursday, October 11th. HC Wainwright set a $5.00 price objective on SCYNEXIS and gave the stock a “buy” rating in a research note on Friday, August 17th. Canaccord Genuity reissued a “buy” rating and set a $4.00 price objective on shares of SCYNEXIS in a research note on Tuesday, August 14th. Finally, Needham & Company LLC set a $5.00 price objective on SCYNEXIS and gave the stock a “buy” rating in a research note on Friday, August 10th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. SCYNEXIS currently has an average rating of “Buy” and a consensus target price of $4.78.
In other SCYNEXIS news, CEO Marco Taglietti bought 25,000 shares of the business’s stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average price of $1.29 per share, with a total value of $32,250.00. Following the completion of the purchase, the chief executive officer now owns 429,000 shares in the company, valued at approximately $553,410. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.25% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “SCYNEXIS (SCYX) Issues Quarterly Earnings Results” was originally reported by Macon Daily and is the property of of Macon Daily. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://macondaily.com/2018/11/14/scynexis-scyx-releases-quarterly-earnings-results.html.
SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
Featured Article: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.